» Articles » PMID: 36295655

The Role of MiR-375-3p, MiR-210-3p and Let-7e-5p in the Pathological Response of Breast Cancer Patients to Neoadjuvant Therapy

Abstract

Prediction of response to therapy remains a continuing challenge in treating breast cancer, especially for identifying molecular tissue markers that best characterize resistant tumours. Microribonucleic acids (miRNA), known as master modulators of tumour phenotype, could be helpful candidates for predicting drug resistance. We aimed to assess the association of miR-375-3p, miR-210-3p and let-7e-5p in breast cancer tissues with pathological response to neoadjuvant therapy (NAT) and clinicopathological data. : Sixty female patients diagnosed with invasive breast cancer at The Oncology Institute "Ion Chiricuță", Cluj-Napoca, Romania (IOCN) were included in this study. Before patients received any treatment, fresh breast tissue biopsies were collected through core biopsy under echographic guidance and processed for total RNA extraction and miRNA quantification. The Cancer Genome Atlas Breast Invasive Carcinoma (TCGA-BRCA) database was used as an independent external validation cohort. miR-375-3p expression was associated with more differentiated tumours, hormone receptor presence and lymphatic invasion. According to the Miller-Payne system, a higher miR-375-3p expression was calculated for patients that presented with intermediate versus (vs.) no pathological response. Higher miR-210-3p expression was associated with an improved response to NAT in both Miller-Payne and RCB evaluation systems. Several druggable mRNA targets were correlated with miR-375-3p and miR-210-3p expression, with upstream analysis using the IPA knowledge base revealing a list of possible chemical and biological targeting drugs. Regarding let-7e-5p, no significant association was noticed with any of the analysed clinicopathological data. Our results suggest that tumours with higher levels of miR-375-3p are more sensitive to neoadjuvant therapy compared to resistant tumours and that higher miR-210-3p expression in responsive tumours could indicate an excellent pathological response.

Citing Articles

Identification of exosomal microRNAs and related hub genes associated with imatinib resistance in chronic myeloid leukemia.

Karabay A, Ozkan T, Karadag Gurel A, Koc A, Hekmatshoar Y, Sunguroglu A Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(12):9701-9721.

PMID: 38916832 PMC: 11582232. DOI: 10.1007/s00210-024-03198-1.


Advances in Cancer Therapy from Research to Clinical Practice-Surgical, Molecular or Systemic Management of Cancer.

Cainap C, Crisan N Medicina (Kaunas). 2023; 59(7).

PMID: 37512120 PMC: 10385133. DOI: 10.3390/medicina59071309.


Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer.

Gianni C, Palleschi M, Merloni F, Bleve S, Casadei C, Sirico M Cancers (Basel). 2023; 15(1).

PMID: 36612091 PMC: 9817806. DOI: 10.3390/cancers15010096.

References
1.
Shintia C, Endang H, Diani K . Assessment of pathological response to neoadjuvant chemotherapy in locally advanced breast cancer using the Miller-Payne system and TUNEL. Malays J Pathol. 2016; 38(1):25-32. View

2.
To N, Nguyen H, Thiolat A, Liu B, Cohen J, Radosevic-Robin N . Radiation therapy for triple-negative breast cancer: emerging role of microRNAs as biomarkers and radiosensitivity modifiers. A systematic review. Breast Cancer Res Treat. 2022; 193(2):265-279. DOI: 10.1007/s10549-022-06533-3. View

3.
Muller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M . Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Res Treat. 2014; 147(1):61-8. DOI: 10.1007/s10549-014-3079-3. View

4.
de Souza Rocha Simonini P, Breiling A, Gupta N, Malekpour M, Youns M, Omranipour R . Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res. 2010; 70(22):9175-84. DOI: 10.1158/0008-5472.CAN-10-1318. View

5.
Tang W, Li G, Li J, Pan W, Shi Q, Xiong D . The role of upregulated miR-375 expression in breast cancer: An in vitro and in silico study. Pathol Res Pract. 2019; 216(1):152754. DOI: 10.1016/j.prp.2019.152754. View